Ads
related to: tpa stroke treatment
Search results
Results From The WOW.Com Content Network
Tissue-type plasminogen activator. Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown. It is a serine protease ( EC 3.4.21.68) found on endothelial cells lining the ...
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter. [5]
The effectiveness and risk of tPA is strongly correlated with the delay between stroke onset and tPA delivery ("door-to-needle time"). Current standards recommend for tPA to be delivered within 4,5 hours of onset, while best results occur when treatment is delivered within 90 minutes of onset. [15]
And when stroke patients are taken to an emergency room, the first treatment doctors often consider is a clot-dissolving medicine called tPA, which can make brain bleeding worse.
Reperfusion therapy is a medical treatment to restore blood flow, either through or around, blocked arteries, typically after a heart attack ( myocardial infarction (MI)). Reperfusion therapy includes drugs and surgery. The drugs are thrombolytics and fibrinolytics used in a process called thrombolysis.
Tenecteplase. Tenecteplase, sold under the trade names TNKase, Metalyse and Elaxim, is an enzyme used as a thrombolytic drug . Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line ( Chinese hamster ovary cells ). Tenecteplase is a 527 amino acid glycoprotein ...
Ads
related to: tpa stroke treatment